EPS growth is an important number as it indicates the future prospects of Onconova Therapeutics. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which at this time is hard to estimate, but revenue growth has been -41.80 % over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Onconova Therapeutics.

Onconova Therapeutics is in the biotechnology industry and is in the healthcare sector. The company CEO is Ramesh Kumar. Onconova Therapeutics Inc is a biopharmaceutical company focusing on discovering and developing novel small molecule product candidates primarily to treat cancer.

Previous Intraday Performance:

The ONTX shares had a previous change of -5.65% which opened at 2.50 and closed at 2.34. It moved to an intraday high of 2.60 and a low of 2.34.

SeekingAlpha:  Onconova: Strong HR-MDS Data At ASH Makes It Highly Interesting Now

Historical Performance:

Over the last five trading days, ONTX shares returned -6.02% and in the past 30 trading days it returned -39.38%. Over three months, it changed -60.07%. In one year it has changed -90.66% and within that year its 52-week high was 39.98 and its 52-week low was 1.69. ONTX stock is 38.46% above its 52 Week Low.

Our calculations result in a 200 day moving average of 6.55 and a 50 day moving average of 3.84. Right now, ONTX stock is trading -64.28% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Onconova: Strong HR-MDS Data At ASH Makes It Highly Interesting Now


The company has a market cap of $13.3m with 5.7m shares outstanding and a float of 4.5m shares. Trading volume was 53,026 shares and has experienced an average volume of 88,805 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Onconova Therapeutics was -42.23 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.78.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.94
06-30-2018:  -1.20
03-31-2018:  -5.09
12-31-2017:  -8.84

Indicators Also to Watch:

Based on the latest filings, there is 73.00% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 2.14

SeekingAlpha:  RCII and ITCI among premarket losers

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -1,050.51%, return on assets is -132.69%, price-to-sales is 12.04 and price-to-book is 1.31.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 6  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 3  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here